TY  - JOUR
AU  - Kalakonda, Nagesh
AU  - Maerevoet, Marie
AU  - Cavallo, Federica
AU  - Follows, George
AU  - Goy, Andre
AU  - Vermaat, Joost S P
AU  - Casasnovas, Olivier
AU  - Hamad, Nada
AU  - Zijlstra, Josée M
AU  - Bakhshi, Sameer
AU  - Bouabdallah, Reda
AU  - Choquet, Sylvain
AU  - Gurion, Ronit
AU  - Hill, Brian
AU  - Jaeger, Ulrich
AU  - Sancho, Juan Manuel
AU  - Schuster, Michael
AU  - Thieblemont, Catherine
AU  - De la Cruz, Fátima
AU  - Egyed, Miklos
AU  - Mishra, Sourav
AU  - Offner, Fritz
AU  - Vassilakopoulos, Theodoros P
AU  - Warzocha, Krzysztof
AU  - McCarthy, Daniel
AU  - Ma, Xiwen
AU  - Corona, Kelly
AU  - Saint-Martin, Jean-Richard
AU  - Chang, Hua
AU  - Landesman, Yosef
AU  - Joshi, Anita
AU  - Wang, Hongwei
AU  - Shah, Jatin
AU  - Shacham, Sharon
AU  - Kauffman, Michael
AU  - Van Den Neste, Eric
AU  - Canales, Miguel A
PY  - 2020
DO  - 10.1016/S2352-3026(20)30120-4
UR  - https://hdl.handle.net/10668/27269
T2  - The Lancet. Haematology
AB  - Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear export, in...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Hydrazines
KW  - Karyopherins
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Middle Aged
KW  - Receptors, Cytoplasmic and Nuclear
KW  - Triazoles
TI  - Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
TY  - research article
VL  - 7
ER  -